Information Technology · Measuring & Controlling Devices, NEC · NYSE · CIK 1809987 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $14.57Day −13.22%Mkt cap $3.8BP/E (FY) 132.5×1Y −34.7%Off 52W high −51.9%Vol (1Y) 56.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,187 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 56.8% growth |
| Short interest13.3% of sh out |
| Days to cover9.8d |
| 13F net flow (QoQ)−0.93% |
| Top-10 13F concentration48.8% |
| Next report (est.)2026-10-27 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)132.5× |
| Sales (TTM)$1.02B |
| Earnings (TTM)$24.5M |
| ROE1.7% |
| Net margin3.1% |
| ROIC2.3% |
| YTD−37.8% |
| 1Y−34.7% |
| 3Y+93.0% |
| Since incept. (ann.)+6.5% |
Total return through 2026-07-29 · series begins 2021-10-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)56.0% |
| Ann. volatility (3Y)45.9% |
| Sharpe (1Y)−0.49 |
| Sharpe (3Y)0.73 |
| Max drawdown (1Y)−51.0% |
| Max drawdown (3Y)−51.0% |
| Beta (3Y vs SPY)1.64 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 37.9M | $704M | 14.50% | −0.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 17.9M | $333M | 6.86% | new |
| T. Rowe Price Investment Management, Inc. | 14.6M | $272M | 5.60% | −16.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.5M | $195M | 4.02% | new |
| STATE STREET CORP | 9.4M | $175M | 3.61% | +2.5% |
| COOPERMAN LEON G | 8.4M | $156M | 3.21% | +0.0% |
| GOLDMAN SACHS GROUP INC | 7.3M | $137M | 2.81% | +40.0% |
| FMR LLC | 6.6M | $122M | 2.51% | −22.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-06-30 | 2026-07-28 | $0.03 | +0.0% | $266.8M | +19.7% |
| 2026-03-31 | 2026-04-28 | −$0.01 | — | $257.6M | +27.5% |
| 2025-12-31 | 2026-02-10 | — | — | $277.4M | +9.1% |
| 2025-09-30 | 2025-10-28 | $0.01 | — | $223.1M | +7.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-27 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Nuclear Safety 66% · Medical 34%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA2.35× |
| Sales growth 3Y8.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
